Phase 4 Chronic Rhinosinusitis Trial, Recruiting NCT04869436 Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 4 Chronic Rhinosinusitis Trial, Recruiting

NCT04869436
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with chronic sinusitis (long-term sinus inflammation) with nasal polyps (small, non-cancerous growths inside the nose)
  • You have a reduced or lost sense of smell
  • Your doctor has recommended a medication called Dupilumab as part of your treatment

Who may not be able to join:

  • Your loss of smell is caused by a cancerous growth in the nose or sinuses
  • Your loss of smell is the result of a physical injury or trauma
  • Your loss of smell has no known cause (confirm with trial site)
  • You currently use or have used cocaine, which can affect the sense of smell
  • Your loss of smell is related to a COVID-19 infection
  • You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Leigh J Sowerby, MD, FRCS, St. Joseph's Hospital London, ON, Canada

Phone: +15196466100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
19 July 2021
Est. completion
1 September 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change from Baseline in the Smell Threshold, Identification and Discrimination (TDI score) at week 12 and week 24.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov